1. participating in any other clinical trial of an experimental agent for covid-19 2. on hydroxychloroquine at any time during hospitalization, or within 180 days of hospitalization for covid-19 regardless of indication 3. history of g6pd deficiency, cirrhosis, long qt syndrome or porphyria of any classification 4. most recent ecg prior to time of screening with qtc of ≥500 msec 5. known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives 6. death anticipated within 48 hours of enrollment 7. inability to obtain informed consent from the patient or designated medical decision maker

1. participating in any other clinical trial of an experimental agent for covid-19 2. on hydroxychloroquine at any time during hospitalization, or within 180 days of hospitalization for covid-19 regardless of indication 3. history of g6pd deficiency, cirrhosis, long qt syndrome or porphyria of any classification 4. most recent ecg prior to time of screening with qtc of ≥500 msec 5. known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives 6. death anticipated within 48 hours of enrollment 7. inability to obtain informed consent from the patient or designated medical decision maker

participating in any other clinical trial of an experimental agent for covid-19 on hydroxychloroquine at any time during hospitalization, or within 180 days of hospitalization for covid-19 regardless of indication history of g6pd deficiency, cirrhosis, long qt syndrome or porphyria of any classification most recent ecg prior to time of screening with qtc of ≥500 msec known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives death anticipated within 48 hours of enrollment inability to obtain informed consent from the patient or designated medical decision maker

participating in any other clinical trial of an experimental agent for covid-19 on hydroxychloroquine at any time during hospitalization, or within 180 days of hospitalization for covid-19 regardless of indication history of g6pd deficiency, cirrhosis, long qt syndrome or porphyria of any classification most recent ecg prior to time of screening with qtc of ≥500 msec known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives death anticipated within 48 hours of enrollment inability to obtain informed consent from the patient or designated medical decision maker

1. participating in any other clinical trial of an experimental agent for covid-19 2. on hydroxychloroquine at any time during hospitalization, or within 180 days of hospitalization for covid-19 regardless of indication 3. history of g6pd deficiency, cirrhosis, long qt syndrome or porphyria of any classification 4. most recent ecg prior to time of screening with qtc of ≥500 msec 5. known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives 6. death anticipated within 48 hours of enrollment 7. inability to obtain informed consent from the patient or designated medical decision maker

1. participating in any other clinical trial of an experimental agent for covid-19 2. on hydroxychloroquine at any time during hospitalization, or within 180 days of hospitalization for covid-19 regardless of indication 3. history of g6pd deficiency, cirrhosis, long qt syndrome or porphyria of any classification 4. most recent ecg prior to time of screening with qtc of ≥500 msec 5. known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives 6. death anticipated within 48 hours of enrollment 7. inability to obtain informed consent from the patient or designated medical decision maker